Loading
NASDAQHealthcareBiotechnology
Latest quote
$18.47
−$0.65 · -3.40%
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Regular session
$18.47
−$0.65 · -3.40%
Regular session · ET · Market data may be delayed.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Day range
Current $18.47
52-week range
Current $18.47
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
79
Undervalued
Sentiment
61
Bullish
Risk
52
Elevated Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Day range
Current $18.47
52-week range
Current $18.47
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.03B USD | 627.24M USD | 285.14M USD | 117.01M USD | 68.83M USD |
| Cost of goods sold | 408.1M USD | 234.58M USD | 144.21M USD | 65.36M USD | — |
| Gross profit | 620.8M USD | 392.66M USD | 140.93M USD | 51.64M USD | 68.83M USD |
| Research and development | 414.7M USD | 413.54M USD | 382.22M USD | 335.65M USD | 313.35M USD |
| Selling, general, and administrative | 341.6M USD | 284.26M USD | 200.93M USD | 174.05M USD | 149.5M USD |
| Operating expenses | 757.3M USD | 695.9M USD | 580.41M USD | 507.26M USD | 461.11M USD |
| Interest income | 40.1M USD | 61.2M USD | 54.49M USD | 8.18M USD | 971K USD |
| Interest expense | 21.4M USD | 21.62M USD | 21.79M USD | 10.8M USD | 900K USD |
| Depreciation and amortization | 28.9M USD | 23.36M USD | 20.45M USD | 18.39M USD | 13.92M USD |
| Operating income | −136.5M USD | −303.24M USD | −439.49M USD | −455.62M USD | −392.29M USD |
| Net income | −296.8M USD | −177.03M USD | −518.25M USD | −446.35M USD | −403.58M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$61.00
230.27% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB23.71M0.23%10.4B USD0.44%$200.16-1.56%
iShares Core MSCI Emerging Markets ETFIEMG15.97M0.01%164.02B USD0.09%$80.3299-2.08%
Invesco Biotechnology & Genome ETFPBE10.51M2.55%412.1M USD0.59%$94.075-0.79%
iShares Core MSCI China ETF2801.HK6.73M0.05%12.36B HKD0.20%HK$22.90-1.21%
Tema Oncology ETFCANC3.9M1.92%203.47M USD0.99%$40.02-1.48%
iShares Core MSCI Asia ex Japan ETF3010.HK3.73M0.01%34.78B HKD0.28%HK$88.72-2.14%
iShares MSCI Emerging Markets ETFEEM3.55M0.01%31.76B USD0.72%$65.915-2.16%
iShares MSCI China ETFMCHI3.53M0.06%6B USD0.59%$51.28-0.70%iShares Biotechnology ETFIBBiShares Core MSCI Emerging Markets ETFIEMGInvesco Biotechnology & Genome ETFPBEiShares Core MSCI China ETF2801.HKTema Oncology ETFCANCiShares Core MSCI Asia ex Japan ETF3010.HKiShares MSCI Emerging Markets ETFEEMiShares MSCI China ETFMCHIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
